Randomized Phase III Study in Low Grade Lymphoma Comparing Maintenance Anti-CD20 Antibody Versus Observation Following Induction Therapy

Trial Profile

Randomized Phase III Study in Low Grade Lymphoma Comparing Maintenance Anti-CD20 Antibody Versus Observation Following Induction Therapy

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Jun 2016

At a glance

  • Drugs Rituximab (Primary) ; Cyclophosphamide; Fludarabine; Prednisone; Vincristine
  • Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Jun 2016 Results of cohort of a patients with indolent lymphoma who received initial induction chemo with cyclophosphamide, vincristine, and prednisone (n=387) published in the Cancer
    • 02 Feb 2010 Planned end date (1 May 2006) added as reported by ClinicalTrials.gov (NCT00003204).
    • 20 May 2009 Lead trial investigator (Horning SJ) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top